Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by Maastricht Radiation Oncology
Sponsor:
Collaborator:
Maastricht University Medical Center
Information provided by (Responsible Party):
Maastricht Radiation Oncology
ClinicalTrials.gov Identifier:
NCT01084785
First received: March 10, 2010
Last updated: December 27, 2012
Last verified: December 2012
  Purpose

The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.


Condition
Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic

Resource links provided by NLM:


Further study details as provided by Maastricht Radiation Oncology:

Biospecimen Retention:   Samples With DNA

whole blood


Estimated Enrollment: 10000
Study Start Date: January 2003
Estimated Study Completion Date: January 2025
Estimated Primary Completion Date: January 2025 (Final data collection date for primary outcome measure)
Detailed Description:

It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • cancer

Exclusion Criteria:

  • not able to comply with follow-up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01084785

Contacts
Contact: Philippe Lambin, Prof PHD 31 (0) 088 44 55 666 philippe.lambin@maastro.nl
Contact: Dirk De Ruysscher, Prof PHD 31 (0) 088 44 55 666 dirk.deruysscher@maastro.nl

Locations
Netherlands
Maastricht Radiation Oncology Recruiting
Maastricht, Limburg, Netherlands
Contact: Dirk De Ruysscher, Prof PHD    31 (0) 88 44 55 666    dirk.deruysscher@maastro.nl   
Contact: Philippe Lambin, Prof PHD    31 (0) 88 44 55 666    philippe.lambin@maastro.nl   
Principal Investigator: Dirk De Ruysscher, Prof PHD         
Sponsors and Collaborators
Maastricht Radiation Oncology
Maastricht University Medical Center
Investigators
Principal Investigator: Dirk De Ruysscher, Prof PHD CCMO
  More Information

No publications provided by Maastricht Radiation Oncology

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Maastricht Radiation Oncology
ClinicalTrials.gov Identifier: NCT01084785     History of Changes
Obsolete Identifiers: NCT00157352, NCT00157365, NCT00157391, NCT00157404, NCT00157417, NCT00157430, NCT00157443, NCT00157456, NCT00157469, NCT00157495, NCT00181337, NCT00181376, NCT00181389, NCT00181402, NCT00181415, NCT00181428, NCT00181441, NCT00181454, NCT00181467, NCT00181480, NCT00181493, NCT00181519, NCT01067872
Other Study ID Numbers: 08-06-23/01
Study First Received: March 10, 2010
Last Updated: December 27, 2012
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht Radiation Oncology:
Cancer
genomics
proteomics

ClinicalTrials.gov processed this record on October 30, 2014